VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of
developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy).
Blood clots cause pain, may require hospitalization and invasive testing, and in some cases
cause death. In fact, blood clots are one of the leading causes of death in patients with
cancer. Furthermore, patients who develop a blood clot require medication to thin the blood
for a prolonged (sometimes indefinite) period of time, and this can disrupt other important
cancer treatments. Studies have shown that using low dose blood thinners to prevent blood
clots during systemic therapy is effective in some patients with cancer. However very few
patients in these studies had genitourinary cancers, therefore physicians in Canada are not
sure if recommending blood thinners to patients with genitourinary cancers is useful or safe.
Safety is a primary concern because blood thinners may cause bleeding, and patients with
genitourinary cancers may have higher risk of bleeding than patients with other types of
cancer. The investigators hypothesize that blood thinners are effective and safe for reducing
blood clots in patients with genitourinary cancers. The objective of this study is to
determine if a large clinical trial testing the effectiveness and safety of low dose blood
thinners for preventing blood clots in patients with genitourinary cancers receiving systemic
therapy is feasible.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Canadian Institutes of Health Research (CIHR) Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network Kidney Cancer Research Network of Canada